Organon completa la adquisicin de Dermavant, que incluye la innovadora terapia dermatolgica VTAMA Crema al 1
| ROIV Stock | USD 12.71 0.02 0.16% |
Slightly above 54% of Roivant Sciences' investor base is interested to short. The analysis of overall sentiment of trading Roivant Sciences stock suggests that many investors are impartial at this time. Roivant Sciences' investing sentiment can be driven by a variety of factors including economic data, Roivant Sciences' earnings reports, geopolitical events, and overall market trends.
Roivant |
Organon , compaa global de asistencia sanitaria con la misin de mejorar la salud de las mujeres a lo largo de toda su vida, ha anunciado
Read at businesswire.com
 |
Roivant Sciences Fundamental Analysis
We analyze Roivant Sciences' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Roivant Sciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Roivant Sciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Number Of Shares Shorted
Number Of Shares Shorted Comparative Analysis
Roivant Sciences is currently under evaluation in number of shares shorted category among its peers. Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
Roivant Sciences Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Roivant Sciences stock to make a market-neutral strategy. Peer analysis of Roivant Sciences could also be used in its relative valuation, which is a method of valuing Roivant Sciences by comparing valuation metrics with similar companies.
Peers
Roivant Sciences Related Equities
| LYRA | Lyra Therapeutics | 10.53 | ||||
| BGNE | BeiGene | 4.29 | ||||
| CGEM | Cullinan Oncology | 2.75 | ||||
| PLRX | Pliant Therapeutics | 2.00 | ||||
| DAWN | Day One | 1.53 | ||||
| BPMC | Blueprint Medicines | 1.35 | ||||
| SNDX | Syndax Pharmaceuticals | 1.27 | ||||
| KRYS | Krystal Biotech | 0.26 | ||||
| ASND | Ascendis Pharma | 0.18 | ||||
| AKRO | Akero Therapeutics | 0.22 | ||||
| INZY | Inozyme Pharma | 0.37 | ||||
| APLS | Apellis Pharmaceuticals | 0.62 | ||||
| PHAT | Phathom Pharmaceuticals | 1.11 | ||||
| RVMD | Revolution Medicines | 1.25 | ||||
| VRDN | Viridian Therapeutics | 1.46 |
Additional Tools for Roivant Stock Analysis
When running Roivant Sciences' price analysis, check to measure Roivant Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Roivant Sciences is operating at the current time. Most of Roivant Sciences' value examination focuses on studying past and present price action to predict the probability of Roivant Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Roivant Sciences' price. Additionally, you may evaluate how the addition of Roivant Sciences to your portfolios can decrease your overall portfolio volatility.